Big win for REGN

Article Excerpt

REGENERON PHARMACEUTICALS, $1,007.96, is a buy. The company (Nasdaq symbol REGN; TSINetwork Rating: Average) (www.regeneron.com; Shares outstanding: 108.4 million; Market cap: $111.1 billion; No dividends paid) avoids costly acquisitions to spur growth. Ins—tead it spends over $4.8 billion annually—or a very high 34% of sales—on R&D. That research outlay continues to pay off. Notably, Regeneron and partner French drug giant Sanofi just got FDA approval to use their Dupixent drug (dupilumab) to help treat adults with chronic obstructive pulmonary disease (COPD). That’s the third-highest cause of death globally. Dupixent brought in $11.6 billion in sales in 2023 for Regeneron and was expected to reach about $17 billion in sales by 2030. But with the approval for COPD, that could rise to over $20 billion in 2030. Regeneron Pharmaceuticals is still a buy. buy…